In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kereos Inc.

www.kereos.com

Latest From Kereos Inc.

Device Financings: Recent Growth, Future Opportunities

A Reprint--see the article of the same name in In Vivo, May 2008.

Device Financings: Recent Growth, Future Opportunities

In Vivo analyzed recent public and private device financings to determine the comparative strengths and weaknesses of the various types of device financings, and further broke down the investments by therapeutic categories to examine what areas are hot and which ones are not. We found that the device industry has rebounded from a dismal public market and is showing strength among both public and private investors, resulting in a sector well-positioned for continued growth.
Medical Device

Tempo Pharmaceuticals Inc.

Tempo Pharmaceuticals produces nano-sized therapeutics designed to deliver a one-two punch: the targeted and sequential release of two drugs at a specific location in the body. Though the technology offers an improved way to deliver drugs, especially highly toxic chemotherapeutics to treat cancer, the company shies away from the drug delivery label. The company says its technology isn't just about getting drug into a tumor; it's about getting the right drug to the right location at the right time to address the microenvironment of the disease.
BioPharmaceutical Strategy

NCI's New Emphasis on Benchtop to Bedside

The private sector, short of funding, is finding NIH a useful source of support. As large-scale biomedical research becomes prevalent and as industry's early-stage R&D productivity falters, both parties have an interest in collaborating more than in the past. But in general, NIH isn't set up to manage the transformation of so many promising discoveries into clinically useful products. It's determined to change that situation with the introduction in October of this year of a "roadmap" for collaborations of many kinds. Even before this event, however, NCI, the largest institute within NIH, had undertaken several public-private programs to expedite development of new products. The institute's experiences illustrate some of advantages and pitfalls of public-private initiatives.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • MRI, NMR
      • Molecular Imaging
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Kereos Inc.
  • Senior Management
  • Robert A Beardsley, PhD, Pres. & CEO
    Gregory M Lanza, MD, PhD, CSO
  • Contact Info
  • Kereos Inc.
    Phone: (314) 633-1879
    4041 Forest Pk. Blvd.
    St. Louis, MO 63108
    USA
UsernamePublicRestriction

Register